Table 1 Clinical characteristics of study population
Variables | Ticagrelor 90 mg (n = 171) | Ticagrelor 60 mg (n = 178) | Clopidogrel 75 mg (n = 176) | P-value |
|---|---|---|---|---|
Age (years) | 63.5 ± 7.4 | 65.3 ± 8.2 | 64.9 ± 7.1 | 0.469 |
Gender (female), n(%) | 62 (36.3%) | 68 (38.2%) | 67 (40.3%) | 0.741 |
Body mass index (Kg/m2) | 23.8 ± 3.4 | 23.5 ± 3.8 | 24.2 ± 3.9 | 0.869 |
Diabetes Mellitus, n(%) | 52 (30.4%) | 58 (32.6%) | 56 (31.8%) | 0.910 |
Hypertension, n(%) | 92 (53.8%) | 85 (47.8%) | 82 (46.6%) | 0.363 |
Current smoker, n(%) | 69 (40.4%) | 75 (42.1%) | 72 (40.9%) | 0.937 |
Previous MI, n(%) | 82 (48.0%) | 80 (44.9%) | 78 (44.3%) | 0.772 |
Previous ischemic CVA, n(%) | 39 (22.8%) | 45 (25.3%) | 38 (21.6%) | 0.710 |
Previous GI bleeding, n(%) | 7 (4.1%) | 8 (4.5%) | 5 (2.8%) | 0.716 |
Peptic Ulcer, n(%) | 21 (12.3%) | 25 (14.0%) | 24 (13.6%) | 0.886 |
LVEF(%) | 43.2 ± 5.5 | 44.4 ± 6.7 | 43.9 ± 5.8 | 0.863 |
NYHA 2–3 on admision, n(%) | 115 (67.3%) | 109 (61.2%) | 112 (63.6%) | 0.499 |
eGFR, ml/min/1.73 mm2 | 64.5 ± 21.7 | 65.1 ± 21.9 | 63.9 ± 22.4 | 0.782 |
CRUSADE score | 32.1 ± 5.2 | 33.4 ± 5.5 | 32.8 ± 6.2 | 0.792 |
Medication | ||||
ACEI/ARB, n(%) | 80 (46.8%) | 75 (42.1%) | 82 (46.6%) | 0.622 |
Beta-blockers, n(%) | 75 (43.9%) | 69 (38.8%) | 78 (44.3%) | 0.515 |
Statin, n(%) | 165 (96.5%) | 170 (95.5%) | 166 (94.3%) | 0.634 |
PPI, n(%) | 166 (97.1%) | 174 (97.8%) | 170 (96.6%) | 0.807 |